Nona Biosciences Unveils Deal With AstraZeneca

Recently, Nona Biosciences announced that it has signed a licence deal with AstraZeneca which will be utilised to develop cancer targeted treatments.

Nona Biosciences will get $19 million upon the conclusion of the sale in accordance with the conditions of the deal. Nona is qualified to earn tiered royalties on net sales, in addition to a further $10 million in possible short-term milestone compensation and up to $575 million upon meeting specific research, regulatory, and commercial objectives. Furthermore, in the event that AstraZeneca exercises these choices, Nona is qualified to get compensation for the option programmes.

Chairman of Nona Biosciences explained: “We are delighted to announce this agreement with AstraZeneca, global leaders in developing tumor targeted therapies, to maximize the potential of our novel antibodies”

They continued “This agreement further validates our leading antibody discovery platform, and we look forward to seeing our antibodies developed into potential new medicines for cancer patients.”

Senior Vice President of AstraZeneca commented: “The global license agreement with Nona Biosciences is an exciting opportunity to further develop these antibodies derived from Nona’s innovative biologics discovery engine into novel tumor targeted therapies using AstraZeneca’s industry-leading capabilities.”